GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

GRI Bio, Inc. Common Stock

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

National Science Foundation

GRI Bio, Inc.

Our CEO, Dr. Marc Hertz, highlights our novel approach to #immunemodulation. Watch the full video here: https://bit.ly/3FvbDJn  

#NKT #AutoimmuneDisease #InflammatoryDisease #FibroticDisease

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis.

https://bit.ly/3GvZu7M 
#IdiopathicPulmonaryFibrosis #IPF #FibroticDisease

Access our library of scientific publications for a comprehensive review of our data. https://bit.ly/3OhuOf8  

#AutoimmuneDisease #PulmonaryDisease #FibroticDisease

#WhatThisMeans: Drs. Marc Hertz and Al Agro, CEO and CMO of GRI Bio, Inc., highlight the Company’s recent IND clearance for lead program targeting #idiopathicpulmonaryfibrosis. 

https://lnkd.in/eUEkB7DC
#IPF #NKT #FibroticDisease

GRI Bio Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant #NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.

https://bit.ly/47we2Qm 
#IdiopathicPulmonaryFibrosis #IPF #FibroticDisease

We hope your Thanksgiving table is full of your favorite food and surrounded by your favorite people.

Regulating #NKT cells is a selective approach to #immunomodulation via resetting the immune response. Learn more here: https://bit.ly/3pRUJAu  

#AutoimmuneDisease #PulmonaryDisease #FibroticDisease

GRI Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update.

https://bit.ly/47ce5kt 
#NKT #AutoimmuneDisease #PulmonaryDisease #FibroticDisease

Email alerts make it easy to stay up to date! Sign up here: https://bit.ly/45GwuVq  

#NKT #AutoimmuneDisease #PulmonaryDisease #FibroticDisease

We are dedicated to advancing new therapies through innovative approaches for the treatment of #inflammatory, #fibrotic and #autoimmune diseases. 

#NKT

	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Jan '24	Mar '24
revenue								5.39M -
cost of revenue		18K -	169K 838.89%			2K -	1K 50%	15K 1,400%	1K 93.33%
gross profit		-18K -	-169K 838.89%			-2K -	-1K 50%	5.38M 538,000%	-1K 100.02%
selling and marketing expenses								569K -	-1K 100.18%
general and administrative expenses	1.36M -	130K 90.46%	123K 5.38%	1.61M 1,205.69%	2.47M 53.99%	5.05M 104.37%	1.25M 75.27%	980K 21.60%	962K 1.84%
selling general and administrative expenses	1.36M -	130K 90.46%	123K 5.38%	1.61M 1,205.69%	2.47M 53.99%	5.05M 104.37%	1.25M 75.27%	965K 22.80%	961K 0.41%
research and development expenses	1.27M -	59K 95.36%	63K 6.78%	61K 3.17%	-124K 303.28%	880K 809.68%	1.19M 35.11%	1.05M 12.03%	933K 10.80%
other expenses							250K -	746K 198.40%
cost and expenses	2.63M -	189K 92.82%	186K 1.59%	1.67M 796.24%	2.35M 40.91%	5.93M 152.62%	2.44M 58.90%	2.03M 16.93%	1.90M 6.47%
operating expenses	2.63M -	189K 92.82%	186K 1.59%	1.67M 796.24%	2.35M 40.91%	5.93M 152.62%	2.44M 58.90%	2.01M 17.55%	1.89M 5.82%
interest expense	1K -	106K 10,500%			47K -	934K 1,887.23%
ebitda	-2.62M -	-189K 92.77%	-185K 2.12%	-1.94M 950.81%	-2.29M 17.59%	-5.93M 159.49%	-2.48M 58.13%	-2.01M 19.04%	-1.89M 5.82%
operating income	-2.63M -	-189K 92.82%	-186K 1.59%	-1.67M 796.24%	-2.35M 40.91%	-5.93M 152.62%	-2.44M 58.90%	-2.03M 16.93%	-1.90M 6.47%
depreciation and amortization	19K -	-18K 194.74%	1K 105.56%	48K 4,700%	63K 31.25%	2K 96.83%	1K 50%	15K 1,400%	1K 93.33%
total other income expenses net	-1K -	-106K 10,500%	-165K 55.66%	-602K 264.85%	-47K 92.19%	122K 359.57%	296K 142.62%	22.00K 92.57%	8K 63.63%
income before tax	-2.63M -	-295K 88.80%	-351K 18.98%	-2.27M 546.44%	-2.40M 5.60%	-6.75M 181.55%	-2.14M 68.32%	-2.00M 6.22%	-1.89M 5.84%
income tax expense	1K -	18K 1,700%		-325K -	47K 114.46%	934K 1,887.23%	-52K 105.57%	1.61M 3,192.31%
net income	-2.64M -	-295K 88.81%	-351K 18.98%	-2.27M 546.44%	-2.44M 7.67%	-6.75M 176.14%	-2.14M 68.32%	-2.00M 6.22%	-1.89M 5.84%
weighted average shs out	2.96M -	2.96M 0%	2.96M 0%	64.20K 97.83%	64.20K 0%	345.40K 437.99%	589.21K 70.59%	645.74K 9.59%	3.20M 395.56%
weighted average shs out dil	2.96M -	2.96M 0%	2.96M 0%	64.20K 97.83%	64.20K 0%	345.40K 437.99%	589.21K 70.59%	645.74K 9.59%	3.20M 395.56%
eps	-0.89 -	-0.10 88.79%	-0.12 20.24%	-35.34 29,350.00%	-38.05 7.67%	-19.53 48.67%	-3.63 81.41%	-3.10 14.60%	-0.59 80.97%
epsdiluted	-0.89 -	-0.10 88.79%	-0.12 20.24%	-35.34 29,350.00%	-38.05 7.67%	-19.53 48.67%	-3.63 81.41%	-3.10 14.60%	-0.59 80.97%

COM:GRIBIO

GRI Bio, Inc.

Last Close

1.27

26/07 20:00

Market Cap

1.59M

Beta: -

Volume Today

457.28K

Avg: -

Preview